Provided are nucleic acids and vectors that collectively encode various gene products related to converting styrene to polyhydroxybutyrate (PHB). In some embodiments, the nucleic acids and vectors collectively encode a styrene monooxygenase polypeptide, a flavin reductase polypeptide, a styrene-oxide isomerase polypeptide, and a phenylacetaldehyde dehydrogenase polypeptide, an acetyl-CoA C-acetyltransferase polypeptide, a 3-ketoacyl-ACP reductase polypeptide, a class I poly(R)-hydroxyalkanoic acid synthase polypeptide, and optionally an influx porin polypeptide. Also provided are systems and methods for producing PHB from styrene, methods and systems for remediating polystyrene waste. In some embodiments, the systems are in vivo systems.

The present invention is in the field of cell therapy and provides compositions and methods for treating cancer and/or viral infections in patients. The invention provides lymphocytes comprising a synthetic polynucleotide encoding at least one iron regulatory protein and, optionally, a chimeric antigen receptor. The invention further provides methods for producing these lymphocytes and administering them to patients.

The present disclosure provides highly efficient, non-invasive, and reversible methods for selectively enriching pluripotent cells (e.g., human pluripotent cells and mouse pluripotent cells) in a cell population using a glutamine-deficient medium. The presently disclosed methods have the advantageous of efficiently enriching pluripotent cells in a heterogenous cell population without altering the biological properties of any individual cells.

A modified vertebrate cell comprising a vertebrate cell encased in reversibly interlinked metal-organic framework (MOF) nanoparticles, and methods of making and using the modified cell, are provided.

The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.

The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine.

This application relates to non-human primate (NHP) induced pluripotent stem cell (IPSC)-derived hepatocytes, for example, Cynomolgus monkey (Macaca fascicularis) induced pluripotent stem cell-derived hepatocytes, and methods of producing the same. Moreover, this application relates to methods of using NHP IPSC-derived hepatocytes for drug screening, drug safety assessment and in models of infection.

The present disclosure provides methods for generating an in vitro model of cholestatic liver disease and uses of the same. In some embodiments, the methods involve an in vitro culture system for producing hepatocyte-like cells from pluripotent stem cells.

Provided herein are compositions and processes for producing compositions from an algae that overproduces protoporphyrin IX (PPIX). Also provided are methods of growing PPIX overproducing algae, methods of isolating PPIX-containing portions from algae cultures and compositions and methods of making food products with PPIX produced by algae. Provided herein are strains and methods to select strains that overproduce PPIX. Also provided are compositions, including edible compositions that include PPIX produced from algae. Specifically, the algal strain over-producing PPIX is an engineered strain of The algal biomass may be used for preparing meat analogues wherein the PPIX compound imparts a meat-like colour and flavour.

The present invention relates to a method for treating hemoglobinopathy in an individual, comprising: (a) an evaluation step: the evaluation step comprises evaluating the ability of a first population of modified CD34-positive hematopoietic stem cells/progenitor cells to produce a desired level of γ-globin or fetal hemoglobin after differentiation, the modified CD34-positive HSPCs of the first population being derived from the individual and being modified to reduce BCL11A function; and (b) a treatment step: the treatment step comprises administering to the individual a second population of modified CD34-positive HSPCs, the modified CD34-positive HSPCs being derived from the individual and being modified to reduce BCL11A function. At the same time, the invention also relates to a method for treating hemoglobinopathy in individuals, a method for selecting individuals suffering from hemoglobinopathy for treatment using the modified CD34-positive HSPCs of the second population, and a method for determining whether an individual suffering from hemoglobinopathy is suitable or unsuitable for treatment using the second population of modified CD34-positive HSPCs derived from the individual and modified to reduce the function of BCL11A.